恆泰裕集團(08081.HK)預期一季度溢利不超過500萬港元
格隆匯5月6日丨恆泰裕集團(08081.HK)公吿,集團預期其業績將由截至2021年3月31日止3個月虧損約4662.4萬港元轉虧為盈,於截至2022年3月31日止3個月錄得溢利不超過500萬港元。
主要由於(i)集團出售其於協盟有限公司全部權益,致使集團移動互聯網業務業績有所改善,協盟有限公司為公司前附屬公司,其直至集團於2021年12月完成出售前一直處於虧損狀態;(ii)集團分佔其其中一間聯營公司截至2022年3月31日止3個月溢利較截至2021年3月31日止3個月溢利約128.9萬港元有所增加;及(iii)集團於截至2021年3月31日止3個月出售8137.8萬股康健國際醫療集團有限公司(其股份於聯交所主板上市,股份代號:3886)股份產生虧損總額約903.4萬港元,而於截至2022年3月31日止3個月並無有關虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.